Gilead Sciences (GILD) Research & Development (2009 - 2026)
Gilead Sciences posted quarterly Research & Development of $1.4 billion for Q1 2026, down 0.51% year-on-year from $1.4 billion in Q1 2025, and down 13.38% on a QoQ basis from $1.6 billion in Q4 2025.
Gilead Sciences (GILD) has 18 years of Research & Development data on file, last reported at $1.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 0.51% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $5.8 billion (changed 0.47% YoY), and the FY2025 full-year result was $5.8 billion, down 1.83% from the prior year.
- Research & Development for Q1 2026 stood at $1.4 billion, down from $1.6 billion in the prior quarter.
- Across five years, Research & Development topped out at $1.6 billion in Q4 2024 and bottomed at $1.1 billion in Q2 2022.
- The 5-year median for Research & Development is $1.4 billion (2023), against an average of $1.4 billion.
- The widest annual swing landed in 2023, when Research & Development rose 27.68%; it then decreased 9.28% in 2025.
- A 5-year view of Research & Development shows it stood at $1.5 billion in 2022, then dropped by 9.04% to $1.4 billion in 2023, then grew by 16.55% to $1.6 billion in 2024, then dropped by 3.47% to $1.6 billion in 2025, then decreased by 13.38% to $1.4 billion in 2026.
- The last three Research & Development figures came in at $1.4 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.58 Bn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 1.49 Bn |
| Mar 31, 2025 | 1.38 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Sep 30, 2024 | 1.40 Bn |
| Jun 30, 2024 | 1.35 Bn |
| Mar 31, 2024 | 1.52 Bn |
| Dec 31, 2023 | 1.41 Bn |
| Sep 30, 2023 | 1.46 Bn |
| Jun 30, 2023 | 1.41 Bn |
| Mar 31, 2023 | 1.45 Bn |
| Dec 31, 2022 | 1.55 Bn |
| Sep 30, 2022 | 1.15 Bn |
| Jun 30, 2022 | 1.10 Bn |
| Mar 31, 2022 | 1.18 Bn |
| Dec 31, 2021 | 1.36 Bn |
| Sep 30, 2021 | 1.10 Bn |
| Jun 30, 2021 | 1.09 Bn |
| Mar 31, 2021 | 1.06 Bn |
| Dec 31, 2020 | 1.47 Bn |
| Sep 30, 2020 | 1.16 Bn |
| Jun 30, 2020 | 1.30 Bn |
| Mar 31, 2020 | 1.00 Bn |
| Dec 31, 2019 | 1.10 Bn |
| Sep 30, 2019 | 1.03 Bn |
| Jun 30, 2019 | 995.00 Mn |
| Mar 31, 2019 | 1.06 Bn |
| Dec 31, 2018 | 852.00 Mn |
| Sep 30, 2018 | 939.00 Mn |
| Jun 30, 2018 | 1.19 Bn |
| Mar 31, 2018 | 937.00 Mn |
| Dec 31, 2017 | 172.00 Mn |
| Sep 30, 2017 | 789.00 Mn |
| Jun 30, 2017 | 864.00 Mn |
| Mar 31, 2017 | 931.00 Mn |
| Dec 31, 2016 | 68.00 Mn |
| Sep 30, 2016 | 200.00 Mn |
| Jun 30, 2016 | 1.48 Bn |
| Mar 31, 2016 | 68.00 Mn |
| Dec 31, 2015 | 757.00 Mn |
| Sep 30, 2015 | 743.00 Mn |
| Jun 30, 2015 | 818.00 Mn |
| Mar 31, 2015 | 696.00 Mn |
| Dec 31, 2014 | 1.05 Bn |
| Sep 30, 2014 | 630.00 Mn |
| Jun 30, 2014 | 584.00 Mn |
| Mar 31, 2014 | 595.00 Mn |
| Dec 31, 2013 | 552.22 Mn |
| Sep 30, 2013 | 546.24 Mn |
| Jun 30, 2013 | 523.90 Mn |
| Mar 31, 2013 | 497.63 Mn |
| Dec 31, 2012 | 439.71 Mn |
| Sep 30, 2012 | 465.83 Mn |
| Jun 30, 2012 | 396.24 Mn |
| Mar 31, 2012 | 458.21 Mn |
| Dec 31, 2011 | 402.24 Mn |
| Sep 30, 2011 | 290.07 Mn |
| Jun 30, 2011 | 282.40 Mn |
| Mar 31, 2011 | 254.45 Mn |
| Dec 31, 2010 | 392.76 Mn |
| Sep 30, 2010 | 230.44 Mn |
| Jun 30, 2010 | 231.07 Mn |
| Mar 31, 2010 | 218.66 Mn |
| Dec 31, 2009 | 239.65 Mn |
| Sep 30, 2009 | 269.86 Mn |
| Jun 30, 2009 | 241.64 Mn |
| Mar 31, 2009 | 188.78 Mn |